Results 11 to 20 of about 2,872,365 (306)

A qualitative study of experiences with physical activity among people receiving opioid agonist therapy [PDF]

Substance Abuse Treatment, Prevention, and Policy
Background Physical or mental health comorbidities are common among people with substance use disorders undergoing opioid agonist therapy. As both a preventive and treatment strategy, exercise offers various health benefits for several conditions ...
Einar Furulund, Siv-Elin Leirvåg Carlsen, Karl Trygve Druckrey-Fiskaaen, Tesfaye Madebo, Lars T Fadnes, Torgeir Gilje Lid   +5 more
doaj   +5 more sources

Healthy eating among people on opioid agonist therapy: a qualitative study of patients’ experiences and perspectives [PDF]

BMC Nutrition
People with substance use disorders often have unhealthy diets, high in sweets and processed foods but low in nutritious items like fruits and vegetables, increasing noncommunicable disease risks.
Einar Furulund, Karl Trygve Druckrey-Fiskaaen, Siv-Elin Leirvåg Carlsen, Tesfaye Madebo, Lars T. Fadnes, Torgeir Gilje Lid   +5 more
doaj   +5 more sources

Oxytocin Reduces Noradrenergic-Induced Opioid-Like Withdrawal Symptoms in Individuals on Opioid Agonist Therapy [PDF]

Biological Psychiatry Global Open Science
Background: Intranasal administration of the neuropeptide oxytocin has been explored as a potential therapeutic agent for substance use disorder including opioid use disorder (OUD).
Brian J. Gully, Zoe E. Brown, Rivkah Hornbacher, Joshua C. Brown, Sudie E. Back, Elinore F. McCance-Katz, Robert M. Swift, Carolina L. Haass-Koffler   +7 more
doaj   +5 more sources

Experiences of non-prescribed opioid use during opioid agonist therapy: an interpretative phenomenological analysis [PDF]

Addiction Science & Clinical Practice
Background Although the goal of opioid agonist therapy is typically understood by clinicians to be the cessation of the use of non-prescribed opioids, many people taking opioid agonist therapy continue to use other opioids.
Sarah Clarke, Kelly Holloway, Daniel Werb, Nav Persaud   +3 more
doaj   +5 more sources

Initiation of opioid agonist therapy after hospital visits for opioid poisonings in Ontario. [PDF]

CMAJ, 2023
Background: Emergency department visits and hospital admissions for opioid toxicity are opportunities to initiate opioid agonist therapy (OAT), which reduces morbidity and mortality in patients with opioid use disorder (OUD). The study objectives were to
Hu T, McCormack D, Juurlink DN, Campbell TJ, Bayoumi AM, Leece P, Kent JT, Gomes T.   +7 more
europepmc   +4 more sources

Retention in Opioid Agonist Therapy Among First Nations People.

JAMA Netw Open
Key Points Question What is the duration of treatment retention among First Nations people in Ontario, Canada, initiating methadone and buprenorphine-naloxone treatment and what factors are associated with retention?
Holton A, Hamzat B, McCormack D, Bragg S, deGonzague B, Mecredy G, Campbell T, Antoniou T, McGregor L, Bertram J, Gomes T.   +10 more
europepmc   +4 more sources

Evaluating the Impact of Increased Dispensing of Opioid Agonist Therapy Take-Home Doses on Treatment Retention and Opioid-Related Harm among Opioid Agonist Therapy Recipients: A Simulation Study

Systems, 2023
Modified opioid agonist therapy (OAT) guidelines that were initially introduced during the COVID-19 pandemic allow prescribers to increase the number of take-home doses to fulfill their need for physical distancing and prevent treatment discontinuation ...
Narjes Shojaati, Nathaniel D. Osgood
doaj   +4 more sources

Precautions in the management of opioid agonist therapy: from target population characteristics to new formulations and post-marketing monitoring – a focus on the Italian system

Drugs in Context, 2023
Opioid use disorder (OUD) is a serious medical condition with vast social, health and economic impact. Individuals with OUD are prescribed opioid agonist therapies, such as methadone, levomethadone, buprenorphine or naloxone/buprenorphine, to reduce the ...
Guido Mannaioni, Fabio Lugoboni
doaj   +2 more sources

Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province

BMC Psychiatry, 2022
Background The last decade has shown a remarkable increase in the rates of illicit opioid use in Canada and internationally, which is associated with large increases in opioid related morbidity and mortality.
Joseph Sadek, Joseph Saunders
doaj   +2 more sources

Navigating Opioid Agonist Therapy among Young People who use Illicit Opioids in Vancouver, Canada

International Journal of Drug Policy, 2022
Background Opioid agonist therapy (OAT) has been shown to reduce opioid use and related harms. However, many young people are not accessing OAT. This study sought to explore how young people navigated OAT over time, including periods of engagement ...
Danya Fast, Andreas Pilarinos, Kora DeBeck   +2 more
exaly   +2 more sources